Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook

42°
- Mammoth Lakes, CA (93546)
  Today
  
  Sun and clouds mixed. High near 45F. Winds light and variable..
  
  Tonight
  
  Clear skies. Low near 20F. Winds light and variable.
  
  Updated: January 28, 2026 @ 2:48 pm
- Full Forecast

Site search

Home
News
Sports/Outdoors
Events
- Archives
Obituaries
Classifieds
- Place an ad
E-Edition
Special Sections
- Eastern Sierra Fishing Guide
- 2024 Summer Olympics

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ensysce Biosciences Inc (OP:ENSCW)

0.0036 +0.0016 (+80.00%)

Streaming Delayed Price Updated: 10:37 AM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences Inc

< Previous 1 2 Next >

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 07, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 08, 2024

Via ACCESSWIRE

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

October 02, 2024

Via ACCESSWIRE

Ensysce Biosciences Presenting at Upcoming Meetings

September 24, 2024

Via ACCESSWIRE

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

September 13, 2024

Via ACCESSWIRE

Ensysce Biosciences Provides Mid-Year 2024 Update

July 23, 2024

Via ACCESSWIRE

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

July 09, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

June 25, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

June 06, 2024

Via ACCESSWIRE

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

June 03, 2024

Via ACCESSWIRE

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024

Via ACCESSWIRE

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 13, 2024

Via ACCESSWIRE

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

April 19, 2024

Via ACCESSWIRE

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 09, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

February 15, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

November 16, 2023

Via ACCESSWIRE

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

October 24, 2023

Via ACCESSWIRE

Ensysce Biosciences to Participate in Upcoming Industry Events

June 06, 2023

Via ACCESSWIRE

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

January 25, 2024

Via ACCESSWIRE

Ensysce Biosciences Issues 2024 Shareholder Letter

January 08, 2024

Via ACCESSWIRE

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

June 27, 2023

Via ACCESSWIRE

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

February 01, 2023

Via ACCESSWIRE

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

January 25, 2023

Via ACCESSWIRE

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

January 04, 2023

Via ACCESSWIRE

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

December 19, 2022

Via ACCESSWIRE

Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational

January 23, 2023

Via ACCESSWIRE

Ensysce Biosciences Issues 2023 Shareholder Letter

January 11, 2023

Via ACCESSWIRE

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

December 07, 2022

Via ACCESSWIRE

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

December 05, 2022

Via ACCESSWIRE

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

November 14, 2022

Via ACCESSWIRE

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Local Events
Obituaries
Multimedia
Online Features

Services

Contact Us
Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather
California Privacy Notice

Contact Information

MammothTimes.com
645 Old Mammoth Road, Suite A
Mammoth Lakes, CA 93546
Phone: 760-934-3929

Advertising

Retail Sales: egalanski@mammothtimes.com
Classified Sales: sales@mammothtimes.com

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Consent Preferences

Mammoth Lakes, CA (93546)

Today

Tonight

Ensysce Biosciences Inc (OP:ENSCW)

Press Releases about Ensysce Biosciences Inc

Sections

Services

Contact Information